Lack of Efficacy of Pegylated Interferon Monotherapy for Hepatitis C in Patients With End-Stage Renal Disease on Dialysis.-临床诊疗知识库

Lack of Efficacy of Pegylated Interferon Monotherapy for Hepatitis C in Patients With End-Stage Renal Disease on Dialysis.

| 浏览：35

作者：

Jenny, Sauk；Donald M, Jensen；Smruti R, Mohanty；Nancy, Reau；K Gautham, Reddy；Helen S, Te

来源：

Gastroenterology & hepatology 2006 年 2卷 7期

标签：

Hepatitis C dialysis end-stage pegylated interferon renal disease renal failure

Objectives To evaluate the efficacy, safety and tolerability of pegylated interferon monotherapy for chronic hepatitis C virus (HCV) in patients who are on dialysis. Methods From the University of Chicago Clinical Hepatology Database dated May 2001 to July 2005, 13 patients on dialysis with hepatitis C who have been treated with pegylated interferon were identified. Demographic and laboratory data were obtained from medical records. Patients received pegylated interferon alfa-2a at 135 µg subcutaneous (SQ) weekly (n = 8) or pegylated interferon alfa-2b at 1 µg/kg SQ weekly (n = 5). Side effects from the medication were noted. Results There were 7 men and 6 women, with a mean age of 54±11 years; 11 patients (85

知识库介绍

临床诊疗知识库该平台旨在解决临床医护人员在学习、工作中对医学信息的需求，方便快速、便捷的获取实用的医学信息，辅助临床决策参考。该库包含疾病、药品、检查、指南规范、病例文献及循证文献等多种丰富权威的临床资源。

详细介绍

临床诊疗知识库现支持机构用户及个人包时用户开通服务。如需开通机构账号，请机构管理员联系我们，联系电话：010-58882667；个人包时开通请直接点击“个人包时订购”，开通后即可使用。

相似文献